key: cord-0831420-3cy7u0sv authors: Poonkuzhi Naseef, Punnoth; Elayadeth-Meethal, Muhammed; Salim K. T, Mohammed; Anjana, A; Muhas, C; Vajid K, Abdul; Saheer Kuruniyan, Mohamed title: Therapeutic Potential Of Induced Iron Depletion Using Iron Chelators In Covid-19 date: 2021-12-13 journal: Saudi J Biol Sci DOI: 10.1016/j.sjbs.2021.11.061 sha: c2698fd884d066ebce311b2f4cfd822381ee87c1 doc_id: 831420 cord_uid: 3cy7u0sv Ferritin, which includes twenty-four light and heavy chains in varying proportions in different tissues, is primarily responsible for maintaining the body's iron metabolism. Its normal value is between 10 and 200 ngmL(-1) in men and between 30-300 ngmL(-1) in women. Iron is delivered to the tissue via them, and they act as immunomodulators, signaling molecules, and inflammatory markers. When ferritin level exceeds 1000 µgL(-1), the patient is categorized as having hyperferritinemia. Iron chelators such as deferiprone, deferirox, and deferoxamine are currently FDA approved to treat iron overload. The inflammation cascade and poor prognosis of COVID-19 may be attributed to high ferritin levels. Critically ill patients can benefit from deferasirox, an iron chelator administered orally at 20-40 mgkg(-1) once daily, as well as intravenous deferoxamine at 1000 mg initially followed by 500 mg every 4 to 12 hours. It can be combined with monoclonal antibodies, antioxidants, corticosteroids, and lactoferrin to make iron chelation therapy effective for COVID-19 victims. In this article, we analyze the antiviral and antifibrotic activity of iron chelators, thereby promoting iron depletion therapy as a potentially innovative treatment strategy for COVID-19. Iron is one of the most important components of hemoproteins and is essential for oxygen transport in the electron transport chain and hepatic metabolism in cytochrome oxidase. A physiologic iron level within the normal range is crucial to prevent disruptions in oxygen transportation, oxidative phosphorylation, and subsequent metabolic impairments [1] . The amount of serum ferritin is an optimal diagnostic marker for iron overload or iron deficiency, as as well as septic shock. As these syndromes involve similar laboratory, clinical, and therapeutic manifestations, hyperferritinemia is likely a contributing factor to the development of these conditions [2] . Globally, COVID-19, which is caused by SARS-CoV-2, has posed a serious threat to humans. In COVID-19 patients, having an elevated serum ferritin concentration of more than 300 µgL -1 ninefold increased the risk of death [3] . These markers are used to identify the severity of the hyperferritinemia conditions and their relationship to COVID-19. Due to its typical immunomodulatory properties, this condition is associated with a variety of immunemediated diseases [4] . The most commonly used iron-chelating agents in treating hyperferritinemia are deferiprone, deferoxamine, and deferasirox. Iron chelators have been shown to significantly enhance iron chelation and catabolize ferritin, whilst concurrently decreasing macrophage-derived cytotoxicity and supplementing antioxidant capacity, which could be beneficial in alleviating COVID-19 structured pathology [5] . In addition to understanding their importance in hyperferritinemia treatment, we aimed to determine how they might be used to decrease COVID 19 mortality. The purpose of our presentation was to encourage clinicians to consider iron chelation therapy as a strategy for managing COVID-19 and its secondary complications. An iron chelation treatment program aimed at improving the clinical outcomes in patients with COVID-19 can hasten advancements in the scientific field. The iron stored in serum ferritin is a biological form of iron that as a factor in iron incorporation, but recent research shows that Lferritin has a stimulatory effect on cell proliferation, independent of iron availability [8] . The proportion of L or H subunits varies with the cell type and biological status, with a high concentration of Hsubunits found in the heart and kidneys and a high concentration of L-subunits found in the liver and spleen [9] [10] . Ferritin synthesis is regulated by cytokines at all stages of gene expression, including cell division, expansion, inflammation, and integration [11] . The residual tissue receptors are embodied to bind only the H-ferritin, unlike those expressed on hepatic cells which bind both L and H subunits [12] . During laboratory animal experiments, it was determined that H-chain phagocytosis receptors were on mucin domain TIM-2 and T-cell immunoglobulins within kidney, liver, and B and T lymphocyte cells [13] . Recent studies have confirmed that Scara5 is a scavenger that can act on a variety of substrates, favorably L-ferritin, as opposed to TIM-2 [14] . Still's disease [15] . For women, the normal range is 10-200 ngmL -1 , while for men the normal range is 30-300 ngmL -1 [16] . When an iron level falls below 12 ngmL -1 , the body has exhausted its iron reserves, and when it reaches 3000 ngmL -1 or greater, there has been liver injury in conjunction with iron overload. It is important to note that the main site for iron storage in a living cell has a high capacity for holding iron in its ferric state (Fe 3+ ). In its core, the molecule can contain about 4500 ferric atoms, and can therefore be used as a potentially effective iron delivery system [17] . Despite the fact that transferrin receptors are the primary process of iron uptake in erythroid cells, it was also demonstrated that macrophages can act as a reservoir of iron in hematopoietic prototype cells through ferritin release [18] . According to Sibille et al. (1998) there is the possibility of over 160,000 iron molecules being accumulated in one hepatocyte per minute [19] . H-ferritin exerts immunomodulatory effects by blocking the generation of antibodies by B lymphocytes, preventing the delayed type of hypersensitivity, inhibiting granulocyte hyperendocytosis, and regulating granulomonocytopoiesis [20] . The cytokine IL-10 is produced by lymphocytes to suppress immune response (21) . Based on available evidence, ferritin H-subunits function as critical components of receptor-mediated cell movement and signaling by chemokine receptors [22] . Shen et al. (2021) suggested that exogenous ferritin plays a role in signaling in stellate hepatocytes. In contrast to its traditional role as a ferrous storage molecule, its ancillary role was entirely detached from its iron content in this study [23] . Various conditions, including rheumatoid arthritis, chronic kidney disease, severe infection, and malignancy, would elevate the acute and chronic inflammatory indicator. A lack of iron in inflammatory conditions, conventionally identified as anemia of malignancies and inflammation, is a defense mechanism that prevents tumors and pathogens from utilizing serum iron. Hyperferritinemia refers to an excess of ferritin in the body. There was a lack of consensus on how to interpret these results and the presence of more than 1000 µgL -1 was considered non-specific [25] . A value exceeding 10,000 µgL -1 is considered extreme. The level of transferrin saturation, however, can serve as a valuable tool for identifying iron overload. Transferrin's iron-binding sites are estimated to be a proportion of its total number of iron-binding sites [26] . Ferritin levels higher than 300 µgL -1 are present in about 20% of caucasian men irrespective of age. Age-wise changes in ferritin distribution are most noticeable during menstruation and pregnancy. A ferritin value over 200 µgL -1 is present in 3% of females aged 30 to 50 years, and the incidence increases with age [27] . The diagnosis of hyperferritinemia in several inflammatory, infectious, and malignant conditions is essential to management, treatment, and prognosis. An abnormal ferritin level is present in the metabolic syndrome, obesity, insulin resistance or diabetes mellitus, excessive alcohol consumption and immune-mediated syndromes like hemophagocytic lymphohistiocytosis (HLH) and Still's disease. There are a few factors that contribute to hyperferritinemia caused by iron overload, such as hemochromatosis, dysmetabolic iron overload syndrome, and ironloading anemias [28, 29] . Among the other causes of hyperferritinemia that lead to an iron overload or hyperferritinemia with iron overload are chronic liver diseases which include viral hepatitis, cirrhosis, alcoholic liver disease, and cutanetate dermatitis. The increase of ferritin in malignancy (300 to 1000 µgL -1 ) is associated with the displacement of ferritin constitution to further H-chain enriched strains [29] [30] [31] . The cytosol extract of benign breast carcinoma tissues demonstrated a 10-fold increase in the tissue ferritin content, which illustrated a substantial amount of ferritin in the non-benign epithelium, and sparse amounts in benign tissue. It was found that serum ferritin is an inferior bioavailability marker for iron in chronic renal impairment subjects [33] . The fact that about half of all hemodialysis patients have a value greater than 500 µgL -1 does not indicate a bioavailable iron for erythropoiesis, but inflammation may be the underlying factor [34] . Moreover, serum ferritin levels over 800g/L were associated with a higher malnutrition-inflammation score [35] . Study results showed that 6.7% of the study subjects had ferritin levels above 1000 µgL -1 , which was associated with hepatic A ferritin level above 500 µgL -1 indicates hemophagocytic lymphohistiocytosis (HLH) or hemophagocytic syndrome (HPS). Basically, it consists of a wide range of inherited or acquired disorders characterized by hyperbolized and fatal inflammatory reactions (39) . Hyperferritinemia is attributed to macrophage activation in acute macrophage activation syndrome [40] . Alcoholic patients with hepatic damage have higher levels of serum ferritin [41] . An escalating iron level accompanies viral Hepatitis C infection. An iron deficiency has been established as a critical comorbidity in viral hepatitis disease progression and advancement to liver failure [42] . The serum ferritin concentration in hepatitis C patients, especially those on hemodialysis, indicated severe hepatic impairment [43] . The ferritin range is being evaluated as part of sequential liver biopsy investigation and therapy [44] . Hereditary hyperferritinemia with congenital cataract is a rare autosomal dominant genetic disease characterized by the presence of pre-existing cataract and persistently elevated ferritin levels in blood plasma (1000 to 5000 gL -1 ). In this genetic disorder, the Lferritin gene coding for a protein in the lens membrane is mutated. Iron chelation therapy reduces iron overload due to its disposition in different organs such as the heart and liver after chronic transfusion and is recommended with ferritin level more than 1000 µgL -1 . Deferasirox, deferiprone and deferoxamine are the most distinct US FDA authorized agents. Each of them has its benefits and drawbacks, various disease targets and amount of iron deposition which may alter their choice. Effective chelation confined with labile plasma iron and non-transferrin bound iron aid to avert adverse complications of iron overload and eliminate them through feces and urine [46] [47] . Compared to ferritin or transferrin, Chaberek and Martell state that ligands must have a higher affinity for iron element, and should have a lower affinity for other physiologically important cations than Fe (III) or Fe (II) [48] . Secondly, the compound must be highly bioavailable. Third, the agent should be able to withstand enzymatic and hydrolytic degradation before and after absorption. It is also important for the chelator to be biocompatible without causing side effects [48] . Removal of cell iron depends on membrane permeability and the ability to compete with constituents of cell iron [49] . Clinically, most chelators are ineffective in removing proteins that contain [Fe-S] clusters or heme [50] . However, some chelators can offer significant inhibition to enzymes that require a constant supply of Fe-like ribonucleotide reductase [51] , or enzymes containing mono-or di-Fe centers coordinated to oxygen ligands [50] . Iron chelator that has a notable affinity for iron and a lesser affinity for calcium and magnesium [52] . Treatment with deferasirox should be initiated for values higher than 1,000 gL -1 . The rise in serum ferritin levels is influenced by acute illnesses, chronic inflammation, and fevers, so a transferrin saturation standard of 15-50% may be useful [53] . It is recommended to start with a 20 mgkg -1 low dose for infrequent blood exchanges followed by a 30 mgkg -1 high dosage for frequent blood exchanges. For the switch from deferoxamine to deferasirox, half of the dose of deferoxamine (DFO) must be administered. If serum ferritin concentrations remain below 500 µgL -1 , a dose reduction or interruption of treatment should be considered. Generally, medication-associated adverse reactions include elevations in liver enzymes, digestive disorders, and unproductive increases in creatinine [54] . A medically acceptable iron-chelating agent called trishydroxamate has proven to be effective in long-term iron chelation therapy, such as in beta-thalassemia [55] . The desferrioxamine binding of Fe (III) is highly exclusive, and removes Fe slowly and slowly from hemosiderin and ferritin, except myoglobin, hemoglobin, oxidases, or cytochromes [56] . DFO is not administered orally due to its poor oral absorption capacity and pharmacokinetics. It is recommended to only administer intramuscularly and with continuous intravenous infusions [57] . DFO is transported away from the plasma readily with a biological half-life of 5-10 minutes, which prompted extended subcutaneous infusion [58] . A nocturnal injection of iron results in the excretion of between 20 and 50 mg of iron daily through the feces and urine. Consequently, it can put a damper on subsequent iron accumulation, thus reducing its storage [59] . Even though pediatric patients benefit from these therapies, the infusions are painful, time-consuming, and expensive. Hypotension, abdominal pain, nausea, diarrhea, and vomiting due to chronic treatment are some of the side effects. Patients with inadequate response to other iron chelating agents may find Deferiprone a better alternative. In liver tissue culture studies, chelator ratios lower than iron concentrations confirmed an increase in DNA oxidation with the drug. Dosages between 25 mgkg -1 and 100 mgkg -1 are recommended orally thrice daily [62] . When deferoxamine is not available, it is considered the secondline treatment in primary beta thalassemia patients. In order to treat severe left ventricular dysfunction successfully, a combination of deferiprone and deferoxamine is administered. Side effects include gastrointestinal agranulocytosis or neutropenia and arthralgia [63] . There are different ways to compare the costs of deferasirox and deferiprone therapy: the cost of medicine, the cost of adverse effects associated with treatment, and the cost of laboratory tests. So, deferasirox is the top choice followed by both deferiprone and deferoxamine in second and third place, respectively [64] . However, deferasirox treatment is favored over traditional deferoxamine therapy according to many recent studies [65] . During the early 2020s, a flare-up of the SARS-CoV-2 virus developed into a pandemic risk. COVID-19 disease is characterized by fatigue, fever, dry cough, lung involvement, and pneumonia [66] . A proportion of 14% can have serious problems with dyspnea, hypoxemia, and tachypnea, as well as lung parenchyma with 50% pulmonary infiltrates within 24 to 48 hours in more serious cases. Septic shock, cardiac arrest, respiratory failure, and organ failure of more than one organ can be life-threatening in less than 5% of cases [67] . severe viral infections, sepsis, and graft-versus-host disease [69] . As a proinflammatory mediator, ferritin could instantly trigger the cytokine storm as an exogenous mediator [70] . Hypoferritinemia, therefore, plays a possible pathogenic role in the cascade of COVID-19 infection. Several studies indicate that COVID-19 mortality is likely caused by virally-driven hyperinflammation, which appears to be a significant indicator of severity and prognosis [61, 71] . Inflammation resulting in hyperferritinemia can result in admission to the intensive care unit and high mortality rates [72] . This indicates the need to identify high-risk patients to guide therapeutic intervention to manage inflammation. A higher ferritin value is more likely to be associated with hemophagocytic lymphohistiocytosis in patients with COVID-19 [73] , and ones with attenuated lung lesions are more likely to have this condition [73] . Having a ferritin level more than 700 ngmL -1 could alert clinicians to more work-up required to diagnose cytokine storm syndrome, allowing them to consider therapeutic approaches without delay [74] . [75] . Developing cytokine storm syndrome, needing invasive ventilation, and dying in hospital are more likely in patients with low iron and D-dimer values initially, but increasing over time [76] . The need for ventilation and death are low when initial ferritin and D-dimer levels are high and subsequent time-spaced repeated values are stable or decreasing [77] . In certain susceptible patient groups, immunological and physiological feedback mechanisms may be different during SARS-CoV-2 infections, since genetic susceptibility factors may influence cytokine production [77] . As many countries are experiencing a second or possibly a third wave of COVID-19, repeated measurement of serum ferritin and D-dimer will support the identification of cases in which a cytokine storm is likely to develop and which will require intensive care [78] . It has been most tragic to witness a more aggressive second In a patient with early-onset diabetes mellitus, COVID-19 was associated with rhinoorbital-cerebral mucormycosis and ketoacidosis [87] . Patients with COVID-19 have been observed to exhibit ketoacidosis and ketonemia, despite the absence of diabetes [88] . Ketoacidosis disrupts phagocytosis and promotes iron dislocation from transferrin, which leads to the proliferation of this fungal pathogen . In addition, iron and zinc excessively used as immunity boosters may cause free iron overload [90] . Often referred to as controlled cell death, ferroptosis is a novel that leads to lipid peroxidation [92] . There is evidence that ferroptosis is a pathogenic mechanism in many diseases, such as metabolic diseases, degenerative diseases like Parkinson's disease, ischemic injury, stroke, renal failure, intracerebral hemorrhage and pulmonary diseases [93] . Infection accompanied by pulmonary injury is a significant cause of the disease. Pseudomonas aeruginosa lipoxygenase stimulates PUFA-PE oxidation and bronchial epithelium ferroptosis in host cells [94] . According to a study on ferroptosis-mediated tuberculosis, macrophages infected with Mycobacterium tuberculosis exhibit ferroptosis features [95] . Smoking induces ferroptosis, which eventually leads to chronic COPD as a consequence of resulting nuclear receptor coactivator 4 (NCOA4)-directed ferritinophagy. Iron chelating agents significantly alleviate the symptoms of all the conditions listed above [96] . It is possible to use this process to formulate anticancer drugs that promote cell death in cancerous cells [97] . Viral replication requires iron as the main raw material. Increased iron can result in the above mentioned catalystic reaction generating lethal reactive species that cannot be expelled by glutathione peroxidase (GPX4) at reduced concentrations [98] . The genetic expression of transferrin and iron metabolism are influenced in relation to hypoxic conditions. Regulation of hypoxia-inducible transcription factor (HIF)-1 is tightly associated with their pathways. This protein contains the HIF-1α subunit as an oxygen-responsive regulator and the HIF-1β subunit, also known as aryl hydrocarbon receptor nuclear translocator (ARNT). When oxygen is abundant, the HIF-1α fractional unit undergoes hydroxylation using iron-associated prolyl-hydroxylases (PHDs), which is inhibited when oxygen is scarce. Therefore, it culminates in aggregation of HIF-1α and its displacement to the nucleus, after which it binds to HIF-1β and activates transcription of HIFresponsive genes. By oxidizing iron from PHDs, iron chelating agents, such as quercetin and deferoxamine (DFO), appear to inhibit the HIF-1α hydroxylation, therefore strengthening the protective effects of iron chelation [101] . As a result of the pathogenic scenario linking inflammation, iron, and infection, it is crucial to seek out a possible therapeutic approach to prevent the onset of fibrosis and cytokine storm that occurs specifically in COVID-19 patients. Thus, iron chelation therapy can be considered as a novel approach to treating hyperferritinemia. In addition to binding with serum-free iron, ironchelating agents can also explain the potential choice of COVID-19 treatment in other ways. These mechanisms involve iron removal from iron-binding proteins along with downregulation of hepcidin [103] , and might explain in part why moderate COVID-19 is less likely to cause hyperferritinemia induced by the antiferritin effect [104] . The presence of excessive iron in the blood can lead to a response known as cardiac iron toxicity. Oxidative stress from too much free iron can result in a rise in reactive oxygen species [ROS] production. In iron overload management, iron chelation agents such as deferasirox, deferoxamine, and deferiprone have been employed (Figure 2 ). These agents have different properties that impact their effectiveness. The potential for hyperinflammation should be screened initially using laboratory tests such as C-reactive protein (CRP) above the 10-fold reference range, increasing ferritin at 1000 ngmL -1 , oxygen consumption at 60%, decline in lymphocytes at 1000 10 9 L -1 and declining platelets less than 100 000 × 10 9 L -1 . In addition, the [110] . Through the use of antioxidant therapy, COVID-19 treatment can prevent the increase in reactive oxygen free radicals caused by hyperferritinemia. Together with iron chelation therapy, vitamin C can be used as a supportive treatment [110] . The dose ranged from 10 to 20 g day _1 over eight to ten hours. All patients were gradually discharged with quick recovery after the oxygen saturation index was enhanced simultaneously [110] . In addition to being a member of the transferrin family, lactoferrin is also a naturally occurring iron chelator since lactoferrin contains more pertinence to binding iron than transferrin. Positively-charged compartments in its structure are ideally suited for Fe [III] binding, which makes it an appropriate treatment option. As well as influencing the immune system, lactoferrin also reduces inflammatory response by regulating ROS and cytokine production. Through its ability to inhibit heparan sulfate proteoglycan binding, LF also shows antiviral qualities [111] . Additionally, Janus kinase [JAK] inhibitors have also been proposed for dealing with severe COVID-19 infections. According to a recent study, baricitinib therapy led to significant reductions in serum cytokines IL-6, TNF, and IL-1b. Baricitinib has been approved for use in combination with antivirals such as remdesivirin in adults and pediatric patients with severe COVID-19 [112] . Corticosteroids have been shown to reduce the mortality of severe COVID-19 cases in multiple studies, including the recovery trials. In patients requiring mechanical ventilation, dexamethasone treatment for up to 10 days had a notable effect on 28-day mortality [113] . Treatment with cytokine blockade could lead to a decreased level of IL-6 cytokine, which correlates positively with inflammatory factors including D-dimer, ferritin, and CRP, which can be probable causes of hyperferritinemia [114] . COVID-19 patients with elevated serum free iron are at risk of secondary infections like mucormycosis. In a study conducted by Ibrahim et al. (2006) , deferiprone was compared to liposomal amphotericin B (LAmB) for controlling mucormycosis in mice with diabetic ketoacidosis [115] . Studies have found that a daily dose of deferiprone or LAmBat of 100 mgkg -1 on average improved survival when compared with a placebo. The fungal burden in the brain was reduced by both drugs in comparison to placebo. Deferiprone was found to be as effective as LAmB at restoring survivability of experimental animals [114] . In one way or another, every therapeutic option comes with pros According to our review article, iron and its storage molecule The relationship between iron homeostasis and COVID-19 must be further elucidated in the current pandemic scenario. And, the necessity of iron chelation therapy should be emphasized for better mitigating cytokine storm associated with COVID-19. We also recommend future experimental studies that demonstrate the consequence of hyperferritinemia on the cardio-respiratory wellbeing and fatality of COVID-19 victims. Hyperferritinemia and inflammation. International immunology COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? Autoimmunity reviews Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages Ferritin as prognostic marker in COVID-19: the FerVid study SARS-CoV-2 Neuronal Invasion and Complications: 232:111197 Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations. Scientific reports Assessment of serum ferritin as a biomarker in COVID-19: bystander or participant? Insights by comparison with other infectious and noninfectious diseases Comparative analysis of two ferritin subunits from blunt snout bream Characterization, expression, iron depriving and bacteriostatic activity. Fish & shellfish immunology When does the cytokine storm begin in COVID-19 patients? A quick score to recognize it Reductive mobilization of iron from intact ferritin: mechanisms and physiological implication Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3) Interactions of ferritin with scavenger receptor class A members Clinical features and prognostic factors of adult secondary hemophagocytic syndrome: Analysis of 47 cases Optimal Serum Ferritin Level Range: iron status measure and inflammatory biomarker Iron metabolism. Anaesthesia & Intensive Care Medicine Transferrin receptors in erythropoiesis Interactions between isolated hepatocytes and Kupffer cells in iron metabolism: a possible role for ferritin as an iron carrier protein Iron and ferritin modulate MHC class I expression and NK cell recognition. Frontiers in immunology Potential role of MRN-100, an iron-based compound, in upregulating production of cytokine IL-10 in human dendritic cells to promote an anti-inflammatory response in vitro Ferritin: an inflammatory player keeping iron at the core of pathogen-host interactions. Microorganisms N6-methyladenosine modification regulates ferroptosis through autophagy signaling pathway in hepatic stellate cells Limitations of serum ferritin in diagnosing iron deficiency in inflammatory conditions Hyperferritinemia in critically ill COVID-19 patients-is ferritin the product of inflammation or a pathogenic mediator? Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease. Alimentary pharmacology & therapeutics Hyperferritinemia: causes and significance in a general hospital Description of the British Society for Haematology. Investigation and management of a raised serum ferritin Extremely high serum ferritin: an instrumental marker of masquerading adult-onset Still's disease with hemophagocytic syndrome. The American journal of case reports Reevaluating the role of ferritin in the diagnosis of adult secondary hemophagocytic lymphohistiocytosis. European journal of haematology Prognostic value of ferritin-to-hemoglobin ratio in patients with advanced non-small-cell lung cancer Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease Ferritin in kidney and vascular related diseases: Novel roles for an old player Serum ferritin< 70 μg/L predicts functional iron deficiency in patients with chronic kidney disease Extremely elevated serum ferritin levels in a university hospital: associated diseases and clinical significance. The American journal of medicine Elevated serum ferritin is not specific for hemophagocytic lymphohistiocytosis Hemophagocytic lymphohistiocytosis in critically ill patients Ferritin index is a strong prognostic marker in adult hemophagocytic lymphohistiocytosis. International journal of clinical practice Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management. Pediatric Drugs Diagnosis and treatment of genetic HFE-hemochromatosis: the Danish aspect iron disturbances in chronic liver diseases other than haemochromatosispathogenic, prognostic, and therapeutic implications. Alimentary pharmacology & therapeutics Correlation Between Serum Ferritin and Viral Hepatitis in Thalassemia Patients Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease Hereditary Hyperferritinemia-Cataract Syndrome in 3 Generations of a Family in East Tennessee. Case reports in hematology Iron Chelation therapy as a modality of management New perspectives in iron chelation therapy for the treatment of neurodegenerative diseases Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one Natural Iron Chelators as Potential Therapeutic Agents for the Treatment of Iron Overload Diseases Trace Elements and Their Effects on Human Health and Diseases Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox Iron Chelation in Transfusion-Dependent Patients With Low-to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Annals of internal medicine A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major. Transfusion and Apheresis Science The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability. Scientific reports Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior Deferoxamine ameliorates adipocyte dysfunction by modulating iron metabolism in ob/ob mice Combating iron overload: a case for deferoxamine-based nanochelators A novel star like eight-arm polyethylene glycol-deferoxamine conjugate for iron overload therapy Combating iron overload: a case for deferoxamine-based nanochelators The iron chelating agent, deferoxamine detoxifies Fe (Salen)-induced cytotoxicity Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease. Scientific reports Deferiprone for the treatment of transfusional iron overload in thalassemia. Expert review of hematology Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. PloS one Comparison of deferiprone to deferasirox and deferoxamine to cardiac and hepatic T2* MRI in thalassemia patients: evidence-based case report Clinical Characteristics of Coronavirus Disease Detection of SARS-CoV-2 in different types of clinical specimens Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet Covid-19 and autoimmunity Activities of serum ferritin and treatment outcomes among COVID-19 patients treated with vitamin C and dexamethasone: an uncontrolled single-center observational study Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. American journal of respiratory and critical care medicine Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis & rheumatology Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of clinical investigation Risk factors for mortality of coronavirus disease-2019 (COVID-19) patients in two centers of Hubei province, China: A retrospective analysis. PloS one Disentangling the dynamical underpinnings of differences in SARS-CoV-2 pathology using within-host ecological models. PLoS pathogens Prognostic Values of Serum Ferritin and D-Dimer Trajectory in Patients with COVID-19 Explained in 10 charts: How Covid cases are rising, spreading during 2nd wave COVID-19) situation reports Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet Clinical presentations, management and outcomes of rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19: a multi-centric study. Ophthalmic plastic and reconstructive surgery When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis Black fungus infection stalks states COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19 COVID-19 infection may cause ketosis and ketoacidosis. Diabetes, Obesity and Metabolism Mucormycosis (the black fungus) during COVID-19 pandemic: growing concerns of immunosuppressive therapy and uncontrolled diabetes mellitus Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India Ferroptosis: mechanisms, biology and role in disease Ferroptosis: molecular mechanisms and health implications. Cell research Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium A major role for ferroptosis in Mycobacterium tuberculosis-induced cell death and tissue necrosis Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis Ferroptosis, a new form of cell death: opportunities and challenges in cancer Ferritinophagy/ferroptosis: Iron-related newcomers in human diseases SARS-CoV-2 infection: can ferroptosis be a potential treatment target for multiple organ involvement? Cell death discovery Mitochondrial dysfunction promotes aquaporin expression that controls hydrogen peroxide permeability and ferroptosis Platelet HIF-2α promotes thrombogenicity through PAI-1 synthesis and extracellular vesicle release. haematologica Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatric Rheumatology COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clinics and practice Depriving iron supply to the virus represents a promising adjuvant therapeutic against viral survival. Current clinical microbiology reports Connecting the dots: interplay of pathogenic mechanisms between COVID-19 disease and Mucormycosis Role of Iron Desferrioxamine Treatment on Final Height in Children with Transfusion Dependent Thalassemia Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience Shanghai Government Officially Recommends Vitamin C for COVID-19 Iron bond bovine lactoferrin for the treatment of cancers and anemia associated with cancer cachexia. InAdvances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents Baricitinib restrains the immune dysregulation in patients with severe COVID-19. The Journal of clinical investigation Dexamethasone in hospitalized patients with Covid-19 Deferiprone iron chelation as a novel therapy for experimental mucormycosis An Unusual Cause of Gastrointestinal Perforation in an Adolescent Patient with Beta-Thalassemia on Deferasirox and SARS-CoV-2 Infection Gastrointestinal symptoms associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis. Internal and emergency medicine The authors extend their appreciation to the Deanship of Scientific Not applicable. There is no conflict of interest.